{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000026","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.479753+00:00","generated_at":"2026-05-31T16:16:52.456693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91","bullets":["Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.","Net revenue $14.462B (+4.3% reported, +5.6% operational); Immunology up 2.3% as Humira -29.8% offset by Skyrizi +44.8% and Rinvoq +55.8%.","Neuroscience portfolio up 14.7% to $2.162B; Aesthetics flat at $1.390B.","FY2024 adjusted EPS guidance raised to $10.71-$10.91 from $10.61-$10.81, including $0.60 IPR&D impact.","Recent events: Robert Michael became CEO July 1; FDA approved Skyrizi for UC; FDA CRL for ABBV-951 Parkinson's; acquisitions of Landos and Celsius."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000026","json":"https://secwatch.observer/filing/0001551152-24-000026.json","markdown":"https://secwatch.observer/filing/0001551152-24-000026.md","text":"https://secwatch.observer/filing/0001551152-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/0001551152-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/abbv-20240725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:16:52.456693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}